Evaluating treatment outcomes for colorectal cancer patients using an immunomodulator

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the survival and treatment outcomes of colorectal cancer patients receiving anti-cancer therapies, comparing those treated with and without an immunomodulator called Astragalus Polysaccharide Injection. Colorectal cancer is a prevalent condition with often unsatisfactory treatment results, and this research aims to explore how targeting the tumor microenvironment may enhance therapy effectiveness. By analyzing clinical data and survival status from medical records, the study seeks to provide insights into the potential benefits of combining immunomodulators with standard cancer treatments. The findings could guide physicians in making informed treatment recommendations for their patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 20 years and older.
* Patients who have been given a diagnosis of colorectal cancer.
* Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.

Exclusion Criteria:

* None

Where it's running

• Taichung Veterans General Hospital
  Taichung, Taiwan Recruiting
• Chung-Shan Medical University Hospital
  Taichung, Taiwan Not yet recruiting

Study contacts

• Study coordinator: Chou-Chen Chen, M.D.
• Email: ccchen24615237@gmail.com

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.